Labiotech.eu

News and Trends 7 Sep 2015

A reliable technology to develop the next generation of GPCR targeted medicines

You must have heard of GPCRs, or more specifically G protein-coupled receptors. Doesn’t ring a bell? You know, it’s this large protein family of receptors that sense molecules outside the cell and trigger an inside signal. A technology called IP-One could give a large advantage to scientists working on GPCR-targeted drugs. We had the opportunity to […]

September 7, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 5 Sep 2015

Genzyme pays another $32.5M for cheating on one of its product’s supposed applications

Genzyme’s $22.28M (€20M) penalty wasn’t enough for the US Department of Justice to resolve its criminal marketing of Seprafilm. Sanofi’s biotech subsidiary will therefore have to pay another $32.5M (€29,2M) to avoid further legal implications. Criminal charges caught Cambridge-based Genzyme by promoting its tape-like Seprafilm for wrong allegations between 2005 and 2010, up until one year […]

September 5, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 5 Sep 2015

Top 5 Things you need to know from outside the EU this week: (Truvada, Nanoclews, CRISPR-Cas9)

Oh hey there…another Top 5 topics you need to know from outside Europe this week. Enjoy and if you have time, give us some feedback! BREAKTHROUGH TABLET PREVENTS HIV INFECTION IN UP TO 92% OF HIGH RISK CASES HIV Tablet ‘Truvada‘: San Francisco health Insurance firm Kaiser Permanente published a study on Tuesday showed out of the […]

September 5, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

Sweden, Vegan and GMO-Free? Check out Simris Alg for your Omega-3

By running an innovative microalgae farm in Hammenhög, Sweden, Simris Alg produces a vegan and GMO-free Omega-3 fatty acid alternative to oily fish derivatives for industry. This Swedish start-up is winning all kinds of awards for their almost too-good-to-be-true approach to dietary Omega-3 oils. The Swedish entrepreneur Fredrika Gullfot (CEO) has improved upon a sustainable alternative to producing Omega-3 oils through a pioneering […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

CAR-T therapy first clinical proof: Patient lives cancer-free 5 years on

A pioneering CAR-T cell therapy study from Novartis and the University of Pennsylvania demonstrates the impressive potential of the next-generation therapy. Five years after the start of the study, three patients have achieved complete remission and remain cancer-free. Here it is, the proof that the hype about CAR-T cell therapy was no hollow promise. Penn’s […]

September 4, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 4 Sep 2015

Gut bacteria growth time can cause disease?

A method of profiling bacterial growth time in the gut’s microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came together from the labs of Dr Elinav and Professor Segal to investigate at the Weizmann Institute of Science, Israel. The millions of bacteria living within our […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Sep 2015

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Adaptimmune has had exciting results regarding the ongoing battle with Synovial Sarcoma. GSK looks to further invest in the expansion of the clinical trial to include two further cohorts. Adaptimmune, with a research base in Oxford (UK) and clinical base in Philadelphia (US), has overcome a milestone in their first cohort for clinical stage I/II T-cell therapy. They […]

September 3, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Sep 2015

Malin has a new Captain aboard to guide and boost its Investments in British Biotechs

Irish life science investment company Malin reshuffles its executive board and gives its former director, Kelly Martin, the new CEO position. The Ex-Elan chief will further push investments in British biotechs. Kelly Martin takes over as CEO of Malin and will balance opportunities and risk in the company’s investments, as well as running day to day […]

September 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Sep 2015

Startups receive €25K investment as part of Merck’s brand new Accelerator Program

Merck – the German healthcare company has announced the 3 start-ups it plans to adopt into its in-house accelerator program. Two of the participants focus on e-health, while the third, Sulfotools, has developed a cleaner and cheaper method of solid-phase protein synthesis (SPPS). Merck has awarded these start-ups with a €25K investment as a ‘silent’ investor as […]

September 3, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Alexion launches a duo of new therapies for ultra-rare diseases in the EU

Thanks to Alexion Pharmaceuticals, two ultra-rare diseases finally got the first treatment in the European Union, namely Lysosomal acid lipase deficiency (LAL-D) and Pediatric-onset hypophosphatasia. Alexion ramps up its product-pipeline. Until now, the Connecticut-based company, which comprises a market cap of about $38.5Bn (€34,2Bn), has lived mostly on sales of Soliris, the most expensive drug on […]

September 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Sep 2015

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Paris based Sanofi has pulled out of a €176M deal with Californian clinical stage biotech Ardelyx. A licensing deal for a program of pre-clinical candidates treating renal diseases and IBS-C, similar to Tenapanor, was revoked. In February 2015, Fresno County’s Ardelyx announced its pharma-baby, Tenapanor, had passed its stage IIB clinical trials in successfully reducing serum levels of phosphate. […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Carmat’s Artificial Heart is now inside three patients – how’s it doing?

So preliminary trial results look good – it could be that the next phase will go forward too. The artificial heart of French pioneer Carmat shows several device failures but overcomes major side effects of former gadgets, such as thromboembolism or haemorrhage. Heart failure is the world’s leading cause of death. In Europe alone, 15 million patients […]

September 2, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

A reliable technology to develop the next generation of GPCR targeted medicines

Genzyme pays another $32.5M for cheating on one of its product’s supposed applications

Top 5 Things you need to know from outside the EU this week: (Truvada, Nanoclews, CRISPR-Cas9)

Sweden, Vegan and GMO-Free? Check out Simris Alg for your Omega-3

CAR-T therapy first clinical proof: Patient lives cancer-free 5 years on

Gut bacteria growth time can cause disease?

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Malin has a new Captain aboard to guide and boost its Investments in British Biotechs

Startups receive €25K investment as part of Merck’s brand new Accelerator Program

Alexion launches a duo of new therapies for ultra-rare diseases in the EU

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Carmat’s Artificial Heart is now inside three patients – how’s it doing?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!